Back to Results

Barinthus Biotherapeutics PLC (BRNS)

Barinthus Biotherapeutics plc is the issuer associated with this NASDAQ-listed depositary receipt representing its common stock. The biotechnology company is engaged in developing immunotherapies and vaccines for use in the United States and the United Kingdom. Its clinical pipeline includes VTP-1000, an antigen-specific immune tolerance candidate being studied in Phase I for celiac disease, and VTP-300, which is in Phase II development for chronic hepatitis B infection. The company also has licensing arrangements with Oxford University Innovation and the U.S. National Institutes of Health related to vaccine and adjuvant technology. Formerly known as Vaccitech plc, the business adopted its current name in November 2023 and was founded in 2016. It is based in Germantown, Maryland.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Next Earnings Date Price-to-Book Ratio Market Cap Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-BRNS
Not available
Not available
Not available
November 5, 2026
0.4x
30.232 M
30.2%
66.7%
-5.5
69.7%
Valuation • Fair Value

Barinthus Biotherapeutics PLC (NASDAQ-BRNS) Fair Value by Valuation Model

No usable valuation estimate is currently available for Barinthus Biotherapeutics PLC (NASDAQ-BRNS); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Barinthus Biotherapeutics PLC (NASDAQ-BRNS). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Barinthus Biotherapeutics PLC (NASDAQ-BRNS)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-31.244 M

Current operating profitability reference.

EBITDA Forecast

-127.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Barinthus Biotherapeutics PLC (NASDAQ-BRNS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Barinthus Biotherapeutics PLC (NASDAQ-BRNS)

Review the financial quality and risk indicators currently supported by the latest data.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-5.5

Lower score that deserves closer risk review.

FCF / Net Income

69.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Barinthus Biotherapeutics PLC (NASDAQ-BRNS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events for Barinthus Biotherapeutics PLC (NASDAQ-BRNS)

Review the upcoming company dates currently supported by the latest data.

Next Earnings Date

November 5, 2026

Days to Earnings

44

How to read events and dividends

Track the upcoming company dates currently available for Barinthus Biotherapeutics PLC (NASDAQ-BRNS). Dividend data is not included in the latest data.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Barinthus Biotherapeutics PLC (NASDAQ-BRNS) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Barinthus Biotherapeutics PLC (NASDAQ-BRNS) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Barinthus Biotherapeutics PLC (NASDAQ-BRNS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Barinthus Biotherapeutics PLC (NASDAQ-BRNS) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Barinthus Biotherapeutics PLC (NASDAQ-BRNS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Barinthus Biotherapeutics PLC (NASDAQ-BRNS) Stock FAQ

Data-supported answers about Barinthus Biotherapeutics PLC (NASDAQ-BRNS), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs

A reliable fair value estimate is not currently available for Barinthus Biotherapeutics PLC (NASDAQ-BRNS). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The next earnings date currently listed for Barinthus Biotherapeutics PLC (NASDAQ-BRNS) is November 5, 2026.

The current market capitalization listed for Barinthus Biotherapeutics PLC is 30.232 M.

The ticker symbol for Barinthus Biotherapeutics PLC is NASDAQ-BRNS, and the stock is listed on NASDAQ.

Barinthus Biotherapeutics PLC (NASDAQ-BRNS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Barinthus Biotherapeutics PLC is 30.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Barinthus Biotherapeutics PLC is 66.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B